NasdaqGS:CRNX

Stock Analysis Report

Executive Summary

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Crinetics Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CRNX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-13.9%

CRNX

2.0%

US Biotechs

-1.1%

US Market


1 Year Return

-40.5%

CRNX

-1.1%

US Biotechs

-13.6%

US Market

Return vs Industry: CRNX underperformed the US Biotechs industry which returned 1.6% over the past year.

Return vs Market: CRNX underperformed the US Market which returned -10.7% over the past year.


Shareholder returns

CRNXIndustryMarket
7 Day-13.9%2.0%-1.1%
30 Day-31.1%-7.8%-17.8%
90 Day-47.2%-6.0%-22.5%
1 Year-40.5%-40.5%-0.3%-1.1%-11.9%-13.6%
3 Yearn/a13.0%10.2%12.1%4.9%
5 Yearn/a-7.6%-11.8%30.5%16.3%

Price Volatility Vs. Market

How volatile is Crinetics Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Crinetics Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

2.79x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CRNX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CRNX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CRNX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CRNX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CRNX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CRNX is overvalued based on its PB Ratio (2.9x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Crinetics Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-19.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CRNX's revenue (58.3% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: CRNX's revenue (58.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CRNX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Crinetics Pharmaceuticals performed over the past 5 years?

-86.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: CRNX is currently unprofitable.

Growing Profit Margin: CRNX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CRNX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CRNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: CRNX has a negative Return on Equity (-43.04%), as it is currently unprofitable.


Next Steps

Financial Health

How is Crinetics Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CRNX's short term assets ($123.3M) exceed its short term liabilities ($8.3M).

Long Term Liabilities: CRNX's short term assets ($123.3M) exceed its long term liabilities ($4.9M).


Debt to Equity History and Analysis

Debt Level: CRNX is debt free.

Reducing Debt: CRNX had no debt 5 years ago.


Balance Sheet

Inventory Level: CRNX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CRNX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CRNX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CRNX has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -63.4% each year.


Next Steps

Dividend

What is Crinetics Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CRNX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CRNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

R. Struthers (57yo)

11.33s

Tenure

US$3,041,435

Compensation

Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in 2008 and serves as its Chief Executive Officer and President since December 2008. Prior to Crinetics, Dr. Struthers served as Senior ...


CEO Compensation Analysis

Compensation vs Market: R.'s total compensation ($USD3.04M) is above average for companies of similar size in the US market ($USD2.13M).

Compensation vs Earnings: R.'s compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
R. Struthers
Founder11.33yrsUS$3.04m4.99% $16.5m
Marc J. Wilson
CFO & Secretary2.25yrsUS$1.03m0.24% $792.5k
Alan Krasner
Chief Medical Officer1.83yrsUS$1.74m0.020% $66.6k
Yun-Fei Zhu
Founder & Vice President of Chemistryno datano datano data
Stephen Betz
Co-Founder & VP of Biologyno datano datano data

2.3yrs

Average Tenure

56yo

Average Age

Experienced Management: CRNX's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
R. Struthers
Founder11.33yrsUS$3.04m4.99% $16.5m
Wendell Wierenga
Independent Chairman of the Board4.5yrsUS$60.14k0.30% $1.0m
Stephen Kaldor
Independent Director4.5yrsUS$40.81kno data
Matthew Fust
Independent Director2.17yrsUS$82.57k0.051% $169.0k
David Clemmons
Member of Scientific Advisory Boardno datano datano data
Anne Klibanski
Member of Scientific Advisory Board3.42yrsno datano data
Weston Nichols
Independent Director2.17yrsUS$21.69kno data
Stephanie Okey
Independent Director0.75yrno datano data
Philip Harris
Member of Scientific Advisory Board1.17yrsno datano data

2.8yrs

Average Tenure

57yo

Average Age

Experienced Board: CRNX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 99.1%.


Top Shareholders

Company Information

Crinetics Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Crinetics Pharmaceuticals, Inc.
  • Ticker: CRNX
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$331.162m
  • Shares outstanding: 24.57m
  • Website: https://www.crinetics.com

Number of Employees


Location

  • Crinetics Pharmaceuticals, Inc.
  • Building 2
  • 10222 Barnes Canyon Road
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRNXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2018
6Z4DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2018

Biography

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing’s diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/02 07:26
End of Day Share Price2020/04/01 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.